Prevalence of promoter CpG island hypermethylaiton in the tissue and serum samples of gliomas patients (%).
| Sample | Methylated MGMT | Mehtylated hMLH1 | Methylated hMSH2 | Overall methylatd |
|---|---|---|---|---|
| Tumor (n = 39) | 18 (46.2) | 4 (10.3) | 8 (20.5) | 25 (64.1) |
| Normal tissue (n = 6) | 0 | 0 | 0 | 0 |
| Serum (n = 32) | 13 (40.6) | 3 (9.4) | 6 (18.8) | 18 (56.3) |
| Normal serum (n = 30) | 0 | 0 | 0 | 0 |
| Paired cases Tissue (n = 21) | 9 (42.9) | 3 (14.3) | 4 (19.0) | 14 (66.7) |
| Serum (n = 21) | 7 (33.3) | 2 (9.5) | 3 (14.3) | 11 (52.4) |
| Percentage of patients with methylation of both tumors and serum (%) | 77.8 | 66.7 | 75 | 78.6 |